Clinical Trials

84 enrolled

Burkitt Lymphoma

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Phase 3 Recruiting

5,951 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT06985485 2026-03-24

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy

26 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05748171 2026-03-20

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

100 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

80 enrolled 1 FDA

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Phase 1 Recruiting

28 enrolled

Burkitt Lymphoma, Recurrence

NCT06287229 2026-02-17

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

Phase 1/2 Recruiting

40 enrolled

Burkitt Lymphoma, Recurrence

NCT06533748 2026-02-12

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

128 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01371630 2025-12-18

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Phase 1/2 Recruiting

276 enrolled

Burkitt Lymphoma

NCT06387121 2025-12-17

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

53 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02877303 2025-11-06

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03104491 2025-06-05

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Phase 1/2 Recruiting

44 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06554626 2024-08-15

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

20 enrolled

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06427330 2024-07-30

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

21 enrolled